Federal Register of Legislation - Australian Government

Primary content

PB 11 of 2018 Determinations/Health as made
This instrument determines an originator brand of a pharmaceutical item for one drug moving to the F2 formulary, effective 1 February 2018.
Administered by: Health
Made 29 Jan 2018
Registered 30 Jan 2018
Tabled HR 05 Feb 2018
Tabled Senate 05 Feb 2018
Date of repeal 02 Feb 2018
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 11 of 2018

National Health (Originator Brand) Amendment Determination 2018 (No. 1)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        29 January 2018

 

 

 

 

 

 

______________________________________

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2018 (No. 1).

(2)     This Determination may also be cited as PB 11 of 2018.

2              Commencement

                This Determination commences on 1 February 2018.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

 

  


Schedule 1     Amendments

(section 3)

[1]                     Schedule 1 (table item 1, 1A and 1B)

Repeal the items, substitute:

 

1

Abacavir with Lamivudine

Kivexa

 

 

1A

Abatacept

Orencia

Orencia Clickject

 

 

1B

Acarbose

Glucobay 50

Glucobay 100

 

 

1C

Aciclovir

Zovirax

Zovirax 200 mg

Zovirax 800 mg